Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor counterattack: fact or fiction?

Frederik H Igney1, Peter H Krammer

  • 1Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany. frederik.igney@schering.de

Cancer Immunology, Immunotherapy : CII
|May 13, 2005
PubMed
Summary

Tumors use CD95L (FasL) to suppress anti-tumor immunity, a "tumor counterattack." However, CD95L expression also triggers inflammation and tumor rejection in mice, highlighting complex immune interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Senescent Cluster in Aged Human Hematopoietic Stem Cell Compartment as Target for Senotherapy.

International journal of molecular sciences·2025
Same author

Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice.

Frontiers in immunology·2024
Same author

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.

Blood·2023
Same author

Anti-GARP Antibodies Inhibit Release of TGF-β by Regulatory T Cells via Different Modes of Action, but Do Not Influence Their Function In Vitro.

ImmunoHorizons·2023
Same author

Molecular analysis of Annexin expression in cancer.

BMC cancer·2022
Same author

Dimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study.

European journal of cancer (Oxford, England : 1990)·2021

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cancer immune evasion is critical for tumor growth.
  • Tumor cells employ mechanisms to suppress anti-tumor immune responses.
  • CD95L (FasL) is an apoptosis-inducing protein implicated in immune modulation.

Purpose of the Study:

  • To explore the dual role of CD95L expression in tumor immune escape.
  • To understand how CD95L contributes to the "tumor counterattack" phenomenon.
  • To review the consequences of CD95L expression on tumor-infiltrating lymphocytes and anti-tumor immunity.

Main Methods:

  • Literature review and synthesis of existing research on CD95L in cancer.
  • Analysis of in vitro studies demonstrating CD95L's effect on T-cell responses.
  • Examination of in vivo studies investigating CD95L-expressing tumors in mouse models.

Main Results:

  • CD95L expression by tumors can eliminate tumor-infiltrating lymphocytes, suppressing anti-tumor immunity.
  • In vitro, CD95L prevents T-cell responses.
  • Conversely, in mice, CD95L-expressing tumors are rapidly rejected and induce inflammation.

Conclusions:

  • CD95L exhibits paradoxical effects on anti-tumor immunity, acting as a double-edged sword.
  • Understanding CD95L's complex role is crucial for developing novel cancer therapies.
  • Further research is needed to reconcile conflicting findings and harness CD95L for therapeutic benefit.

Related Experiment Videos